Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT
A Voluntary Ex-Ante Transparency (VEAT) Notice
by BELFAST HEALTH AND SOCIAL CARE TRUST
- Source
- Find a Tender
- Type
- Contract (Supply)
- Duration
- not specified
- Value
- £1M
- Sector
- HEALTH
- Published
- 09 May 2022
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
Belfast Health and Social Care Trust
Geochart for 2 buyers and 1 suppliers
2 buyers
1 supplier
Description
Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT
Award Detail
| 1 | Advanced Accelerator Applications UK & Ireland (London)
|
CPV Codes
- 33000000 - Medical equipments, pharmaceuticals and personal care products
Indicators
- Award on basis of price and quality.
Legal Justification
No other reasonable alternative or substitute exists for this procurement and the absence of competition is not a result of the artificial narrowing of the parameters of the procurement. Lutetium (177Lu) oxodetreotide (Lutathera) is a licensed radiopharmaceutical for the treatment of unresectable or metastatic, progressive, well-differentiated somatostatin receptor positive gastro-entero-pancreatic neuroendocrine (GEP) tumours in adults. The supplier, Advanced Accelerator Applications (AAA), holds the unique patent and licence for this product. This is the only licenced Peptide Receptor Radionuclide Therapy (PRRT) in Europe.
Reference
- FTS 012066-2022